BioNTech SE (0A3M.IL)
Develops experimental cancer vaccines that train the immune system to fight tumors.
$92.75+0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-12.9%
The outlook
BioNTech trades near the lower end of its 52-week range, with analyst consensus tilted toward Buy. The average price target sits roughly 137% above the current price, though the stock's price movement relative to its moving averages shows mixed signals. At a trailing P/E of 5.2, valuations appear compressed by historical standards.
What’s behind the score
Analyst consensusBuy — 2.4 avg of 15 analysts
Price trendMixed vs its moving averages
52-week range30% of the way from its 52-week low to high
Price targetAvg target +137% vs current price
Analyst price target
~12-month · 15 analysts$219.54average target+136.7% vs now
Now $92.75
Low $134.38High $317.63
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$25.51B
52-wk high
$123.69
52-wk low
$79.51
50-day avg
$91.40
200-day avg
$98.01
Trailing P/E
5.2